Assignee
IMPACT THERAPEUTICS INC
CN9 patents
Top patents by PatentIndex Score
US10874670B2Dec 29, 2020
Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof
IMPACT THERAPEUTICS INC2 citations71
US9926304B2Mar 27, 2018
1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
IMPACT THERAPEUTICS INC3 citations68
US11179392B2Nov 23, 2021
Solid pharmaceutical formulation of PARP inhibitors and use thereof
IMPACT THERAPEUTICS INC3 citations66
US10562889B2Feb 18, 2020
Process for the preparation of 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones
IMPACT THERAPEUTICS INC1 citations61
US11358955B2Jun 14, 2022
1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
IMPACT THERAPEUTICS INC0 citations57
US9102631B2Aug 11, 2015
1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
IMPACT THERAPEUTICS INC3 citations57
US10676468B2Jun 9, 2020
N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors and use thereof
IMPACT THERAPEUTICS INC1 citations56
US10703759B2Jul 7, 2020
8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
IMPACT THERAPEUTICS INC0 citations51
US10316027B2Jun 11, 2019
1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
IMPACT THERAPEUTICS INC0 citations47